Table 5.
Univariate analysis of the median progression-free survival in patients with metastatic nasopharyngeal carcinoma
| Characteristic | n (%) | mPFS | 95% CI | HR | P |
|---|---|---|---|---|---|
| Total | 113 (100) | 8.2 | |||
| Gender | |||||
| Male | 77 (68.1) | 9.2 | 7.968-10.432 | 0.855 | 0.494 |
| Female | 36 (31.9) | 7.6 | 6.196-9.004 | ||
| Age (years) | |||||
| ≤50 | 55 (48.7) | 7.8 | 6.276-9.324 | 0.984 | 0.940 |
| >50 | 58 (51.3) | 9.3 | 8.094-10.506 | ||
| Previous treatment | |||||
| Neoadjuvant or adjuvant chemotherapy | |||||
| Yes | 82 (72.6) | 7.8 | 6.804-8.796 | 0.664 | 0.100 |
| No | 31 (27.4) | 9.8 | 8.858-10.742 | ||
| Time to disease progression (years) | |||||
| ≤1 | 40 (35.4) | 4.5 | 3.510-5.490 | 3.020 | 0.000 |
| >1 | 73 (64.6) | 9.9 | 8.941-10.859 | ||
| ECOG score | |||||
| 0 | 6 (5.3) | 12.6 | 9.447-15.753 | 0.573 | 0.266 |
| 1 | 107 (94.7) | 8.4 | 6.944-9.854 | ||
| Organ involvement | |||||
| Single organ | 24 (21.2) | 13.4 | 9.918-16.882 | 0.29 | 0.000 |
| Multiple organs | 89 (78.8) | 7.8 | 6.920-8.680 | ||
| Liver metastasis | |||||
| Yes | 62 (54.9) | 5.8 | 3.762-7.838 | 0.555 | 0.007 |
| No | 51 (45.1) | 9.8 | 8.858-10.742 | ||
| Lung metastasis | |||||
| Yes | 73 (64.6) | 7.8 | 6.831-8.769 | 0.688 | 0.108 |
| No | 40 (35.4) | 9.4 | 8.483-10.317 | ||
| Grouping | |||||
| Gemcitabine + platinum | 56 (49.6) | 9.7 | 8.844-10.556 | 0.585 | 0.014 |
| Docetaxel + platinum | 57 (50.4) | 7.8 | 6.447-9.153 |
mPFS – Median progression-free survival; CI – Confidence interval; HR – Hazards ratio; ECOG – Eastern cooperative oncology group